Recombinant Human PCSK9 cell lysate
|Product Overview :||Human PCSK9 / NARC1 derived in Human Cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls|
- Gene Information
- Related Products
|Source :||Human cells|
|Preparation method :||Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.|
|Lysis buffer :||Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF|
|Quality control Testing :||12.5% SDS-PAGE Stained with Coomassie Blue|
|Recommended Usage :||1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating.|
|Stability :||Samples are stable for up to twelve months from date of receipt at -80°C|
|Storage Buffer :||50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF|
|Storage Instruction :||Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes.|
|Gene Name :||PCSK9 proprotein convertase subtilisin/kexin type 9 [ Homo sapiens ]|
|Official Symbol :||PCSK9|
|Synonyms :||PCSK9; proprotein convertase subtilisin/kexin type 9; HCHOLA3, hypercholesterolemia, autosomal dominant 3; FH3; NARC 1; NARC1; NARC-1; HCHOLA3;|
|Gene ID :||353175|
|UniProt ID :||Q8NBP7|
|Chromosome Location :||1p34.1-p32|
|◆ Recombinant Protein|
|PCSK9-486R||Recombinant Rhesus PCSK9 Protein (Met1-Gln692), MIgG1 Fc-tagged||+Inquiry|
|PCSK9-005H||Active Recombinant Human PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-410H||Recombinant Human PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-405C||Recombinant Cynomolgus monkey PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-407H||Recombinant Human PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-2564MCL||Recombinant Mouse PCSK9 cell lysate||+Inquiry|
|PCSK9-2306RCL||Recombinant Rat PCSK9 cell lysate||+Inquiry|
|PCSK9-2775RCL||Recombinant Rhesus PCSK9 cell lysate||+Inquiry|
|◆ Assay kits|
|Kit-1807||PCSK9[Biotinylated]-LDLR Binding Assay Kit||+Inquiry|
|Kit-1806||PCSK9(D374T)-LDLR TR-FRET Assay Kit||+Inquiry|
|Kit-1808||PCSK9-LDLR TR-FRET Assay Kit||+Inquiry|
|Kit-0665||PCSK9-BIRC2 in vitro Binding Assay Kit||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.
PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.
This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.
Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.
Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.
PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.
Customer Reviews (0)Write a review
Ask a Question for All PCSK9 Products
Required fields are marked with *
My Review for All PCSK9 Products
Required fields are marked with *